Patents by Inventor Catia Traversari

Catia Traversari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAR NK CELLS
    Publication number: 20220064599
    Abstract: A method of manufacturing of Natural Killer (NK) Cells genetically modified with lentiviral vectors carrying a polynucleotide coding for a Chimeric Antigen Receptors (CARs). CAR-NK cells obtained with the method, and the use of the CAR-NK cells in medicine, in particular for use in a method of treating cancer is also disclosed.
    Type: Application
    Filed: May 29, 2019
    Publication date: March 3, 2022
    Applicant: GLYCOSTEM THERAPEUTICS B.V.
    Inventors: Jan SPANHOLTZ, Nina KOK, Alessandra GATTI, Giuliana VALLANTI, Catia TRAVERSARI
  • Combination
    Publication number: 20170252435
    Abstract: A pharmaceutical product comprising (a) a conjugation product of TNF and a tumour- or tumour vasculature-targeting peptide comprising an NGR, DGR, isoDGR or RGD motif; and (b) a cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-specific targeting domain which targets a tumour antigen.
    Type: Application
    Filed: March 3, 2016
    Publication date: September 7, 2017
    Inventors: Claudio Bordignon, Catia Traversari, Gian Paolo Rizzardi
  • Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3
    Patent number: 7923534
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: April 12, 2011
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • Antigen Transduced T Cells Used as a Delivery System for Antigens
    Publication number: 20080286305
    Abstract: A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.
    Type: Application
    Filed: June 13, 2008
    Publication date: November 20, 2008
    Applicant: MolMed Spa
    Inventors: Catia Traversari, Claudio Bordignon
  • Antigen transduced T cells used as a delivery system for antigens
    Patent number: 7413733
    Abstract: A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: August 19, 2008
    Assignee: MolMed SpA
    Inventors: Catia Traversari, Claudio Bordignon
  • Antigen transduced t cells used as a delivery system for antigens
    Publication number: 20040235172
    Abstract: A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.
    Type: Application
    Filed: April 9, 2004
    Publication date: November 25, 2004
    Inventors: Catia Traversari, Claudio Bordignon
  • Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
    Publication number: 20030228308
    Abstract: A peptide, previously identified as a binding partner of HLA-Cw3 and Cw16, has now been found to bind to HLA-Cw6. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 11, 2003
    Inventors: Yi Zhang, Catia Traversari, Thierry Boon-Falleur, Pierre Van der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6531451
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: March 11, 2003
    Assignees: Ludwig Institute for Cancer Research, Universite Catholique de Louvain
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catia Traversari, Vincent Stroobant, Guy Cornelis, Thiery Boon-Falleur, Pierre van der Bruggen
  • Method for treating cancer by administering MAGE-derived peptides
    Patent number: 6488932
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: December 12, 1995
    Date of Patent: December 3, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules
    Patent number: 6379901
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: April 30, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Method for stimulating CTLs with peptides
    Patent number: 6353089
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These “T-RAS” bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: July 7, 1999
    Date of Patent: March 5, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre van der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer
  • Isolated nonapeptides presented by HLA molecules, and uses thereof
    Patent number: 6222012
    Abstract: The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: April 24, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Etienne De Plaen, Christoph Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde, Pedro Romero
  • Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
    Patent number: 6201111
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 13, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wölfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells
    Patent number: 6034214
    Abstract: The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: March 7, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari
  • Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
    Patent number: 6019987
    Abstract: Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: February 1, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre Van Der Bruggen, Thierry Boon-Falleur, Catia Traversari, Katharina Fleischauer
  • Precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 6001975
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
    Patent number: 5925729
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: July 20, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5856091
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: January 5, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5854203
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
    Patent number: RE40089
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: January 24, 1996
    Date of Patent: February 19, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari